Skip to main content

Advertisement

SpringerLink
Log in

Bladder cancer

Pioglitazone—when is a prescription drug safe?

  • News & Views
  • Published:

From Nature Reviews Urology

View current issue Sign up to alerts

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

In a recent issue of JAMA, Lewis et al. present long-term data on the likelihood of a link between pioglitazone and the risk of bladder cancer and ten other cancers. Their findings contradict previous concerns regarding the safety of pioglitazone, and add to the controversy surrounding interpretation of rare adverse events associated with prescription drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Fontanarosa, P. B., Bauchner, H. & Golub, R. M. Evaluating research on the safety of medical therapies: the responsibility of journals to the health of the public. JAMA 314, 235–236 (2015).

    Article  CAS  Google Scholar 

  2. Sharfstein, J. M. & Kesselheim, A. S. The safety of prescription drugs. JAMA 314, 233–234 (2015).

    Article  CAS  Google Scholar 

  3. Lewis, J. D. et al. Pioglitazone use and risk of bladder cancer and other common cancers in persons With diabetes. JAMA 314, 265–277 (2015).

    Article  CAS  Google Scholar 

  4. Turner, R. M. et al. Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis. Br. J. Clin. Pharmacol. 78, 258–273 (2014).

    Article  CAS  Google Scholar 

  5. Loke, Y. K., Singh, S. & Furberg, C. D. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 180, 32–39 (2009).

    Article  Google Scholar 

  6. Singh, S., Loke, Y. K. & Furberg, C. D. Thiazolidinediones and heart failure: a teleo-analysis. Diabetes Care 30, 2148–2153 (2007).

    Article  CAS  Google Scholar 

  7. Food and Drug Administration. FDA Drug Safety Communication: Updated drug labels for pioglitazone-containing medicines [online], (2011).

  8. Lewis, J. D. et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 34, 916–922 (2011).

    Article  CAS  Google Scholar 

  9. Levin, D. et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis. Diabetologia 58, 493–504 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Norwich Medical School, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, UK

    Yoon Kong Loke & Katharina Mattishent

Authors
  1. Yoon Kong Loke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katharina Mattishent
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yoon Kong Loke.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Loke, Y., Mattishent, K. Pioglitazone—when is a prescription drug safe?. Nat Rev Urol 12, 655–656 (2015). https://doi.org/10.1038/nrurol.2015.237

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2015.237

  • Springer Nature Limited

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Search

Navigation